Regular readers will know that
PTC Therapeutics are trialling a new drug they have developed,
ataluren, that is designed to overrule the premature stop that happens in the development of a protein in genetic disorders due to
nonsense mutations.
We have emailed them a few times to make them aware of TMAU.
This week we will be having a chat on the phone with one of their departments. They will be advising us how to best make an ataluren trial for genetic TMAU nonsense mutation cases attractive to pharmaceutical companies and biotechs who normally do these type of trials. We will let you know how the phone call went in the next few days.
Nonsense mutations usually make up a minority of cases in genetic disorders.
0 comments: